

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI – 400 001.
Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel.: 22618452/22661541, Tel/Fax: 22618327

Date: 11th February, 2020

To,
The Corporate Relations Department
Bombay Stock Exchange Limited
1st Floor, New Trading Wing,
PJ Tower, Dalal Street, Fort
Mumbai – 400001.

Scrip Code: 524516

Sub: Submission of Newspaper clipping of Unaudited Financial Results for the quarter ended 31st December,2019 held at the Board Meeting held on 08th February, 2020.

Dear Sir,

Please find enclosed herewith newspaper clipping of Unaudited Financial Results for the quarter ended 31.12.2019 approved at the Board Meeting held on Saturday, 08th February, 2020 which is published in Navshakti (Marathi) and Free Press Journal (English) on 11th February, 2020 for you records.

Kindly take the note of the same and incorporate the above on your website.

For Bacil Pharma Limited



Jayesh, Ramchandra Patil
Chief Financial Officer

Place: Mumbai

BACIL PHARMA LIMITED

CIN: L24200MH1987PLC043427

Regd. Office: 71, Laxmi Building, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001 Email: bacilpha@yahoo.com Website: www.bacilpharma.com

EXTRACT OF THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2019 (₹ in Lakhs)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31-12-2019 (Unaudited)	30-09-2019 (Unaudited)	31-12-2018 (Unaudited)	31-12-2019 (Unaudited)	31-12-2018 (Unaudited)	31-03-2019 (Audited)
Total Income from operations (Net)	1.97	8.86	1.64	12.45	4.70	9.41
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(24.84)	1.01	(8.90)	(29.30)	(29.15)	34.35
Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(24.84)	1.01	(8.90)	(29.30)	(29.15)	34.35
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(24.81)	0.99	(8.90)	(29.29)	(29.15)	34.24
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(14.38)	(6.28)	1.31	(35.58)	(33.70)	(32.58)
Equity Share Capital (Face Value of ₹ 10 each)	589.00	589.00	589.00	589.00	589.00	589.00
Earning Per Share (before extraordinary items) (of ₹ 10 each) (in ₹) - Not Annualised						
Basic:	(0.42)	0.02	(0.15)	(0.50)	(0.49)	(0.58)
Diluted:	(0.42)	0.02	(0.15)	(0.50)	(0.49)	(0.58)

Note: The above is an extract of the detailed format of Quarter and Nine Months Ended Unaudited Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange website www.bseindia.com & Company website www.bacilpharma.com

FOR BACIL PHARMA LIMITED

Sd/-
PRAKASH SHAH
Director
DIN - 01136800

PLACE : MUMBAI
DATED : February 08, 2020

वचशक्ति
मुंबई, मंगळवार, ११ फेब्रुवारी २०२०

१३

BACIL PHARMA LIMITED

CIN: L24200MH1987PLC043427

Regd. Office: 71, Laxmi Building, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001 Email: bacilpha@yahoo.com Website: www.bacilpharma.com

EXTRACT OF THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2019 (₹ in Lakhs)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31-12-2019 (Unaudited)	30-09-2019 (Unaudited)	31-12-2018 (Unaudited)	31-12-2019 (Unaudited)	31-12-2018 (Unaudited)	31-03-2019 (Audited)
Total Income from operations (Net)	1.97	8.86	1.64	12.45	4.70	9.41
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(24.84)	1.01	(8.90)	(29.30)	(29.15)	34.35
Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(24.84)	1.01	(8.90)	(29.30)	(29.15)	34.35
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(24.81)	0.99	(8.90)	(29.29)	(29.15)	34.24
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(14.38)	(6.28)	1.31	(35.58)	(33.70)	(32.58)
Equity Share Capital (Face Value of ₹ 10 each)	589.00	589.00	589.00	589.00	589.00	589.00
Earning Per Share (before extraordinary items) (of ₹ 10 each) (in ₹) - Not Annualised						
Basic:	(0.42)	0.02	(0.15)	(0.50)	(0.49)	(0.58)
Diluted:	(0.42)	0.02	(0.15)	(0.50)	(0.49)	(0.58)

Note: The above is an extract of the detailed format of Quarter and Nine Months Ended Unaudited Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange website www.bseindia.com & Company website www.bacilpharma.com

FOR BACIL PHARMA LIMITED

Sd/-
PRAKASH SHAH
Director
DIN - 01136800

PLACE : MUMBAI
DATED : February 08, 2020